Celine Cheng

Celine Cheng is a Scientist in Upstream Process Development at ATUM, with expertise in operating and developing single-use bioreactor processes for monoclonal antibodies and bi-specifics. Cheng has extensive experience creating scalable processes that facilitate the transition from R&D to GMP manufacturing and coordinating closely with QA on CAPA investigations. Prior roles include Associate Scientist at 4D Molecular Therapeutics, where responsibilities involved developing and validating cell-based bioassays for AAV-based gene therapies, and Senior Scientist at Samsung Biologics focusing on cell line development. Cheng contributed to cell line development at Resilience, optimizing CHO stable pools, and held research roles at Vitalant, both as a Research Associate and Summer Research Intern, emphasizing assay development in immunology. Cheng holds a Bachelor's degree in Biochemistry from California State University - East Bay.